When it comes to anti-cytomegalovirus therapy, the Lao Xiong version of Valganciclovir is an unavoidable name. As a prodrug of ganciclovir, it offers a more convenient and safer treatment option for patients requiring long-term medication due to its superior oral bioavailability.
How much does the Lao Xiong version of Valganciclovir cost?
The Lao Xiong version of Valganciclovir is available in a specification of 450mg*60 tablets/box, with a price of approximately $139. The specific price may be affected by various factors, and the actual selling price shall prevail.
Drug interactions of Valganciclovir (Valcyte)
When Valganciclovir (Valcyte) is used in combination with other drugs, it may alter each other's plasma concentrations or toxicity profiles through pharmacokinetic or pharmacodynamic interactions, therefore the risks of combination therapy must be carefully evaluated. First, when Valganciclovir is combined with drugs such as zidovudine, mycophenolate mofetil, or azathioprine, the incidence and severity of hematologic adverse reactions such as neutropenia and anemia are significantly increased. These drugs themselves have varying degrees of bone marrow suppression, and their combined use produces additive effects. Second, any nephrotoxic drugs (such as aminoglycoside antibiotics, amphotericin B, non-steroidal anti-inflammatory drugs, etc.) used concurrently with Valganciclovir can impair renal function, thereby slowing the elimination process of ganciclovir from the body, leading to drug accumulation and increased toxicity. Third, probenecid and other drugs excreted via active tubular secretion can competitively inhibit the renal tubular secretion of ganciclovir, reducing its clearance rate, also resulting in elevated plasma concentrations and increased toxicity risk. Fourth, the combination of Valganciclovir with other cytotoxic drugs (such as chemotherapeutic agents) significantly increases the risk of bone marrow suppression, gastrointestinal reactions, and skin adverse reactions, and should generally be avoided. Fifth, the active metabolite of valganciclovir, ganciclovir, can significantly increase the bioavailability of didanosine. When used together, didanosine-related toxicities (such as pancreatitis, peripheral neuropathy) should be closely monitored. Finally, combination with imipenem/cilastatin may increase the potential for seizures; unless absolutely necessary, this combination should be avoided.
Use of Valganciclovir (Valcyte) in special populations
For special populations such as pregnant women, nursing mothers, and children, the use of Valganciclovir (Valcyte) requires strict risk assessment principles. Regarding use in pregnant women, since valganciclovir is rapidly and extensively converted to ganciclovir in the body, no independent reproductive toxicity studies have been conducted for the former. However, in animal studies, ganciclovir has been shown to cause reduced fertility and has clear teratogenic effects. Therefore, all women of childbearing potential are advised to use effective contraception during the entire treatment period. For male patients, given the potential mutagenic effects of valganciclovir on spermatogenesis, barrier contraception (such as condoms) is also recommended during treatment and for at least 90 days after discontinuation. To date, there are no adequate clinical data on the safety of valganciclovir use during human pregnancy. Therefore, pregnant women should avoid using this drug unless, in very exceptional circumstances, the potential therapeutic benefit to the mother is clearly considered to far outweigh the possible harm to the fetus. Regarding use in nursing mothers, no studies have been conducted on the effects of valganciclovir or ganciclovir on perinatal and postnatal infant development. However, based on the properties of the drug, it must be considered that ganciclovir is likely to be secreted into human milk, potentially causing serious adverse reactions in nursing infants. Therefore, when deciding whether to use the drug, the potential benefit of valganciclovir to the nursing mother should be weighed, and a clear choice should be made between discontinuing the drug or discontinuing breastfeeding. Finally, regarding use in children, since safety and efficacy data in Chinese pediatric patients have not been established and pharmacokinetic studies are lacking, valganciclovir is not recommended for children of any age.
